BRAF mutations, particularly BRAF V600E, are rare but clinically significant molecular alterations in intrahepatic cholangiocarcinoma (IHCC), often linked to aggressive disease and poor prognosis. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.